PRTA News and Press, Prothena Corporation plc From 12/07/21

The electric vehicle sector is mostly higher after riding out some negative news yesterday with Lucid Group (LCID -3.3%) disclosing a SEC subpoena and Tesla (TSLA +3.0%) reportedly being probed over solar panel fire risk. Helping to boost sentiment, several Wall Street economists are mak...

Prothena has a drug candidate Birtamimab in phase three trials and is close to approval. The company has a promising pipeline in some high-revenue neurodegenerative disease fields. The company has very promising cash opportunities in the next five years as well as having over $600...

DUBLIN, Ireland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior manage...

Biogen's struggles with Aduhelm - its newly approved Azheimer's therapy - have been well documented - but the company is taking some small steps in the right direction. Meanwhile, Cassava Sciences recently took a significant step to restoring its own reputation - and share price - aft...

Investors are rushing back into electric vehicle stocks after the weekend signing of the bipartisan infrastructure bill. Proterra (PRTA +2.6%), Volta (VLTA +8.4%), GreenPower Motor GP, Electrameccanica Vehicles (SOLO +2.4%), Lordstown Motors (RIDE +5.4%), Electric Last Mile Solutions (MILE -0...

Prothena (NASDAQ:PRTA): Q3 GAAP EPS of $2.13 misses by $0.15. Revenue of $139.17M misses by $0.88M. Press Release For further details see: Prothena EPS misses by $0.15, misses on revenue

Net cash provided by operating and investing activities was $111.9 million in the third quarter and $114.8 million for the first nine months of 2021; Quarter-end cash and restricted cash position was $601.5 million Received $140 million from partner payments in third quarter fro...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s likely going to take a few years to get beyond the stark difference between pre-pandemic and post-pandemic worlds. In the U.S., it’s very much like before and after 9/11. But there are some worthy healthc...

DUBLIN, Ireland, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, announced today that it will report its third quarter and first nin...

DUBLIN, Ireland, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that Chief Financial Officer Tran B. Nguyen has bee...